Journal article
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.
METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and …
Authors
Richeldi L; du Bois RM; Raghu G; Azuma A; Brown KK; Costabel U; Cottin V; Flaherty KR; Hansell DM; Inoue Y
Journal
New England Journal of Medicine, Vol. 370, No. 22, pp. 2071–2082
Publisher
Massachusetts Medical Society
Publication Date
May 29, 2014
DOI
10.1056/nejmoa1402584
ISSN
0028-4793